WO2004022050A1 - 脂質代謝調整剤および飲食物 - Google Patents
脂質代謝調整剤および飲食物 Download PDFInfo
- Publication number
- WO2004022050A1 WO2004022050A1 PCT/JP2003/011293 JP0311293W WO2004022050A1 WO 2004022050 A1 WO2004022050 A1 WO 2004022050A1 JP 0311293 W JP0311293 W JP 0311293W WO 2004022050 A1 WO2004022050 A1 WO 2004022050A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fatty acid
- medium
- chain fatty
- expression
- chain
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a lipid metabolism-related enzyme expression enhancer containing a medium-chain fatty acid and a glycerin fatty acid ester containing a medium-chain fatty acid as an active ingredient, and their foods, drinks, raw materials, and oil / fat compositions. It relates to its use in the pharmaceutical and food sectors.
- Obesity refers to a physical condition in which the intake of energy exceeds the energy expenditure and fat tissue accumulates more than normal.
- various diseases such as diabetes, hypertension, cardiovascular disorders, hyperlipidemia, and atherosclerosis, and is complicated by vascular disorders, neuropathy, reduced resistance, etc.
- the disease may be complicated. From the viewpoint of prevention of these so-called lifestyle-related diseases, etc., research has been conducted on various means for resolving obesity, and various treatments such as diet therapy, exercise therapy, and drug therapy have been developed and implemented.
- activation of this enzyme causes regression of adipose tissue by decomposing small glycerides accumulated in hypertrophied adipose tissue, and is very effective as a means of relieving obesity. Furthermore, since this enzyme is inherent in the body, it can eliminate obesity without adversely affecting the human body. Therefore, the activation of this enzyme or the development of an inducer is very promising.
- the fat and oil composition containing 31% by mass or more of triglycerides having two medium-chain fatty acid residues in the molecule may have low body fat accumulation. It has been reported (see, for example, Japanese Patent Application Laid-Open No. Hei 4-310826, Japanese Patent Application Laid-open No. Hei 8-61080, Japanese Patent Application Laid-Open No. Hei 10-176181).
- medium-chain fatty acids and glycerin fatty acid esters containing Z or medium-chain fatty acids, such as medium-chain triglycerides are associated with lipid metabolism. It has not yet been reported that the enzyme is promoted, and that the body fat is reduced by this function, and that the body fat, particularly subcutaneous fat, has an effect of modifying the body to be easily reduced.
- the present invention provides a lipid metabolism-related enzyme expression enhancer comprising a medium-chain fatty acid and / or a glycerin fatty acid ester containing a medium-chain fatty acid as an active ingredient.
- An object of the present invention is to provide a modifier for a constitution that is easily reduced, and to obtain a food and drink, a raw material, and a fat and oil composition thereof. Disclosure of the invention
- the present inventors have conducted intensive studies to achieve the above object, and found that medium chain fatty acids and / or glycerin fatty acid esters containing medium chain fatty acids suitably metabolize fat accumulated in the body, The present invention has been completed.
- the present invention relates to a lipid metabolism-related enzyme expression enhancer comprising a medium-chain fatty acid and / or a glycerin fatty acid ester containing a medium-chain fatty acid as an active ingredient.
- the present invention relates to a peroxisome / 3 oxidase-enzyme expression enhancer containing a medium-chain fatty acid and a glycerin fatty acid ester containing a medium-chain fatty acid as an active ingredient, and relates to an acyl CoA oxidase expression enhancer.
- the present invention provides a composition having a medium body fatty acid and / or a glycerin fatty acid ester containing a medium chain fatty acid as an active ingredient.
- the present invention relates to a constitution modifying agent for a constitution in which subcutaneous fat is easily reduced.
- the present invention also relates to a food and drink for enhancing expression of a lipid metabolism-related enzyme, comprising a medium-chain fatty acid and Z or a glycerin fatty acid ester containing a medium-chain fatty acid as an active ingredient. Food and drink.
- the present invention also relates to a lipid metabolism-related enzyme expression enhancer raw material containing a medium-chain fatty acid and / or a glycerin fatty acid ester containing a medium-chain fatty acid as an active ingredient.
- the present invention also relates to a lipid composition for enhancing expression of a lipid metabolism-related enzyme, comprising a medium-chain fatty acid and a glycerin fatty acid ester containing Z or a medium-chain fatty acid as active ingredients.
- the present invention also relates to a use for producing a lipid metabolism-related enzyme expression enhancer comprising medium-chain fatty acids and glycerin fatty acid esters containing Z or medium-chain fatty acids as components.
- lipid metabolism-related enzymes is increased by ingesting medium-chain fatty acids and / or glycerin fatty acid esters containing medium-chain fatty acids.
- ingestion of medium-chain fatty acids and glycerin fatty acid esters containing z- or medium-chain fatty acids promotes the expression of oxidative enzymes related to lipid metabolism in peroxisomal mitochondria, which are organelles of hepatocytes, The promotion activity is improved.
- lipid metabolism-related enzymes means that the expression levels of acyl-CO a oxidase, carnitine palmitoyl converting enzyme 2, and long-chain acyl-CO a dehydrase, Shows hyperactivity.
- the body fat is reduced by enhancing the activity and enhancing the body fat decomposition promoting activity, and free fatty acids released into the blood are taken up again by the adipose tissue and are suitably consumed, thereby reducing body fat.
- a body fat particularly a skin Byone fat, can be used as a modifier for a constitution that is easily reduced.
- ACO A oxidase
- acyl CoA dehydrogenase which is responsible for / 3 oxidation in mitochondria, which is also an organelle in hepatocytes, especially long-chain acyl CO dehydrogenase. This activates fatty acid 3 oxidation in mitochondria.
- j3 oxidative enzymes related to lipid metabolism enhances the activity of promoting lipid metabolism, and the fatty acids administered and ingested in the liver and the fatty acids derived from body fat are suitably burned, thereby improving body health. Fat can be reduced.
- acyl COA oxidase which is responsible for / 3 oxidation in peroxisomes, which are subcellular organelles of fat cells, increases as enzymatic activity, and promotes the degradation of very long-chain fatty acids in peroxisomes. Is done. With this ACO, the reduced chain fatty acid enters the mitochondria via carnitine palmitoyltransferase 2 and undergoes further / 3 oxidation.
- UCP 2 uncoupling protein 2
- body fat can be reduced by expressing a / 3 oxidation enzyme related to lipid metabolism.
- the increased expression of oxidizing enzymes promotes the accumulation of fatty acids, and the metabolism of lipids when oxidizing the accumulated fatty acids to produce energy.
- this effect alone has a slimming effect on the human body, it has a body fat low storage function due to an uncoupling protein expression enhancing effect, and therefore, has a suitable slimming effect due to a synergistic effect of these.
- the medium-chain fatty acid and / or the glycerin fatty acid ester containing the medium-chain fatty acid is generally classified into fats and oils, and therefore, the embodiment as a fat and oil composition is preferable.
- the fat and oil composition has a surface as a raw material, a surface as food and drink, and the like, and a surface as a heat medium and seasoning used for cooking.
- Compositions and fats and oils compositions containing high concentrations of medium-chain fatty acids and glycerol fatty acid esters containing ⁇ or medium-chain fatty acids are preferred embodiments as the raw materials for the above-mentioned functional preparations and drinks, and are manufactured and distributed as raw materials. You.
- the glycerin fatty acid ester containing a medium-chain fatty acid refers to any one or more of the constituent fatty acids R1, R2, and R3 represented by the following general formula (I) containing the medium-chain fatty acid described above.
- a glycerin fatty acid ester containing a fatty acid selected from 6 to 24 carbon atoms as a constituent fatty acid is shown.
- glycerin fatty acid triester having all of the constituent fatty acids R1, R2, and R3 represented by the following general formula (I), and glycerin in which any one of the constituent fatty acids 11, 112, and R3 is hydrogen
- Fatty acid diesters consist of glycerin fatty acid monoesters, only one of which is a constituent fatty acid.
- glycerin fatty acid diester having a constituent fatty acid at 1 and R3
- glycerin fatty acid diester having a constituent fatty acid at R1 and R2
- dariserin fatty acid monoester having a constituent fatty acid only at R1 or R3
- a glycerin fatty acid monoester having a constituent fatty acid only in R2 is also included.
- the form containing the medium-chain fatty acid may be any one of the constituent fatty acids R1, R2, and R3 represented by the following general formula (I) consisting of the above-mentioned medium-chain fatty acid; Wherein only one of R2 and R3 comprises a fatty acid selected from C6 to C24; R2 only comprises a fatty acid selected from C6 to C24; R1 and R2 to R3 and that R 2 is a fatty acid selected from 6-24 carbon atoms, c constituent fatty R 1 and R 3 is also. consist fatty acid selected from 6-24 carbon atoms R l, R 2, R 3 Those all having the above-mentioned medium-chain fatty acid form will be described later in detail.
- the content is required to be within a range in which the function can be obtained, and is not particularly limited.
- the content is 0.5% by mass or more, preferably 1% by mass or more, more preferably 5% by mass or more, and further preferably ⁇ 99.9 wt%, preferably especially 10 to 99.9 mass 0/0, and most particularly preferably 13-99. 9% by mass.
- the content is preferably within the above-mentioned range, and it is more preferable that the possibility of adverse effects on the human body is reduced.
- the content is preferably as low as possible for commercial or industrial purposes. For example, the following content at the time of long-term intake can be referred to.
- fatty acid esters in which at least one or more medium-chain fatty acids are bound to glycerin, and specifically designed to identify the position at which the medium-chain fatty acids are bound and the type of other fatty acids Glycerin fatty acid ester (hereinafter, referred to as “structure” or “structural fat”).
- structure fatty acid ester
- structural fat The content of the medium-chain fatty acid, the MLCT, and the content of the structural fats and oils in the preparation containing the MLCT and the structure (structural fat) can be referred to the above.
- the content of the medium-chain fatty acid needs to be in a range in which the function can be obtained, and is preferably in the above range, and the lower the possibility of adverse effects on the human body, the more preferable. Further, the content is preferably as low as possible for commercial or industrial use. '
- the ratio of medium-chain fatty acids to total fatty acids is 3 to 23 mass. /.
- the ratio of medium-chain fatty acids to total fatty acids is 3 to 23 mass. /.
- the ratio of medium-chain fatty acids to total fatty acids is 3 to 23 mass. /.
- Favored properly is 4-2 0 weight 0/0, more preferably 5 to 7% by weight, particularly preferably from 6 to 1 5 mass 0/0, most preferably 7-1 4 wt%, most particularly preferably 8 ⁇ 13% by mass.
- the number of the medium-chain fatty acid residues at positions 1 and 3 is 40% by mass or more, preferably 50% by mass or more, more preferably 60% by mass. % Or more, particularly preferably 70% by mass Above, most preferably 80 mass. /. It is preferable that the amount is above because, for example, the substance is well decomposed and absorbed in the intestinal tract and the like when ingested orally.
- the functional agent, food and drink, or oil / fat composition of the present invention preferably contains a medium-chain fatty acid triglyceride, and if the amount of medium-chain fatty acid is the same, it is preferably MLCT. It is preferable that the structure is designed for the position and position.
- the content can be determined according to the required strength of the function, etc., with reference to the content of the medium-chain fatty acid.
- the content of the medium-chain triglyceride is 3 to 30% by mass, preferably 3 to 23% by mass, preferably 4 to 20% by mass, more preferably 5 to 17% by mass, and particularly preferably 6 to 17% by mass. 15% by weight, most preferably 7 to 14% by weight. /. , Most particularly preferably 8-1 3 wt%, even if the MLCT,. 1 to 80 wt%, preferably 2-70 wt%, more preferably at 3 I 6 0 mass 0/0, particularly preferably 5 to 50 mass 0/0, most favorable Mashiku 7 to 20 mass. /.
- the structure is preferably 1 to 80% by mass, preferably 2 to 70% by mass, and more preferably 3 to 60% by mass. / 0 , particularly preferably 5 to 50% by weight, most preferably 7 to 20% by weight, most preferably 8 to 14% by weight.
- the medium-chain fatty acid triglycerides used in the present invention are generally referred to as MCT (Mediurn Chain Triglycerides).
- a mono- or mixed-acid triglyceride composed of a saturated fatty acid having 6 to 12 carbon atoms, preferably 8 to 10 carbon atoms, such as coconut oil-decomposed fatty acid.
- the triglyceride can be produced by subjecting the above-mentioned medium-chain fatty acid and glycerin to an esterification reaction by a conventional method, but the use of a commercially available product is convenient.
- Examples of the fat and oil composition containing the medium-chain fatty acid triglyceride include common edible fats and oils such as soybean oil, rapeseed oil, oleic rapeseed oil, corn oil, sesame oil, sesame salad oil, perilla oil, linseed oil, peanut oil, Safflower oil, high-oleic safflower oil, sunflower oil, high-oleic sunflower oil, cottonseed oil, grape seed oil, macadamia nut oil, hazelnut oil, capocia seed oil, walnut oil, camellia oil, teaseed oil, egoma oil, borage Oil, olive oil, rice bran oil, wheat germ oil, palm oil, palm kernel oil, coconut oil, cocoa butter, tallow, lard, chicken fat, milk fat, fish oil, seal oil, algae oil, low saturation due to quality improvement
- These fats and oils, hydrogenated fats and fractionated fats and oils and the like are listed.
- the medium-chain fatty acid of the present invention is preferably a fatty acid having 6 to 12 carbon atoms, and examples include caproic acid, caprylic acid, capric acid, and lauric acid. Further, saturated fatty acids having 8 to 10 carbon atoms, particularly, pryprilic acid and pric acid are preferred.
- Glycerin fatty acid esters containing medium-chain fatty acids can be obtained naturally or synthetically.
- glycerin fatty acid esters containing medium-chain fatty acids having 6 to 12 carbon atoms as constituent fatty acids such as palm oil, palm kernel oil and coconut oil, are used as raw materials. It can be produced by transesterification, but is not limited thereto.
- the conditions for the ester bond reaction are not particularly limited, either. For example, it can be obtained by reacting under pressure without using a catalyst and using no solvent. Of course, the reaction using catalysts and solvents However, it is possible to obtain the glycerin fatty acid ester containing the medium-chain fatty acid of the present invention.
- glycerin fatty acid esters containing medium-chain fatty acids can be obtained from the oil seeds of genetically modified plants, or glycerin containing medium-chain fatty acids can be obtained from medium-chain fatty acids obtained from oil-seed plants of genetically modified plants. It is also possible to produce fatty acid esters. It can also be obtained by an enzymatic reaction using an enzyme. In consideration of the flavor, color, and safety of fats and oils, and when taken orally, it is preferable to manufacture them by transesterification with an enzyme, but the present invention is not limited to this.
- composition of the fatty acids at the 1- and 3-positions of the obtained transesterified fat may or may not be biased, but in particular, the more fatty acids at the 1- and 3-positions, the better the decomposition etc. It is preferable because of the tendency.
- MLCT is a glycerin fatty acid ester containing a medium-chain fatty acid, in which the number of medium-chain fatty acids bound to one glycerin is 1 or 2, and the other is a long-chain fatty acid.
- the absorbability, the function in the body, and the like differ depending on the number of medium-chain fatty acids and the positions where they are bonded, and it is preferable to appropriately adjust them according to the purpose.
- MLCT in which a medium-chain fatty acid is bound to one or more of positions 1 and 3, particularly to both, is preferred.
- a fat and oil such as palm kernel oil or coconut oil having a medium chain fatty acid having 6 to 12 carbon atoms as a constituent fatty acid
- transesterification treatment is performed using a lipolytic enzyme (lipase).
- lipase a lipolytic enzyme
- the enzyme include lipases derived from the genus Alcaligenes, Candida, Rhizopus, Mucor or Pseudomonas, and phospholipase A derived from the liver, and lipases derived from the genus Candida or Rhizobus are particularly preferred.
- the type of the enzyme can be appropriately selected depending on the conditions.
- the method for performing the transesterification reaction using a lipolytic enzyme is not particularly limited.
- the temperature is adjusted within the range of 40 to 100 ° C, which is the reaction temperature at which the activity of the lipolytic enzyme is sufficiently exhibited.
- the lipolytic enzyme is added to the mixture at a ratio of 0.05 to 10% by mass, and the transesterification is carried out for 2 to 48 hours.
- This reaction is desirably performed in a nitrogen stream at normal pressure. Completion of the reaction is confirmed by measuring the triglyceride composition of the reaction product by gas chromatography.
- the reaction product is washed with water, dried, and then decolorized and deodorized by an ordinary method.
- the present invention can be produced by mixing a medium-chain fatty acid and / or a glycerin fatty acid ester containing a medium-chain fatty acid, or by mixing and mixing oils and the like containing these.
- the structure can be designed with respect to the type of fatty acid other than the medium-chain fatty acid that binds to glycerin, the position where these bind, and the like.
- Preferred structural fats and oils include, for example, those in which a medium-chain fatty acid is bonded to one or both of the 1- and 3-positions, and a specific fatty acid is bonded to the 2-position.
- a linear fatty acid is preferable, particularly from the viewpoint of natural abundance and the like, and a linear unsaturated fatty acid is more preferable.
- ⁇ -3-unsaturated fatty acids such as eicosatetraenoic acid, eicosapentaenoic acid, docosapentaenoic acid, and docosahexanoic acid, conjugated linoleic acid, and conjugated fatty acids such as a-eleostearic acid.
- Examples of these structural fats and oils include M-oleic acid-M, M-o; linolenic acid-M, M- ⁇ linolenic acid-M, M-eicosapentaenoic acid-M, M-docosapetanic acid-M, M-docosahexaenoic acid-M, M-conjugated linoleic acid-M and the like can be exemplified.
- MLCT and structural fats and oils can be produced by a transesterification reaction, and can be preferably produced using an enzyme having regiospecificity.
- Lipid metabolism-related enzyme expression enhancer of the present invention peroxisome i3 oxidase expression enhancer, acyl CoA oxidase expression enhancer, mitochondrial oxidase enzyme; current enhancer, carnitine palmitoyl transferase 2 expression Enhancers, long-chain acyl C ⁇ ⁇ dehydrogenase expression enhancers, modifiers for reducing body fat, and modifiers for reducing subcutaneous fat include medium-chain fatty acids and It is characterized by containing a glycerin fatty acid ester containing a medium-chain fatty acid, and can be used for any purpose. For example, it can be used in a wide range of fields such as pharmaceuticals, quasi-drugs, and health foods.
- the amount of the medium-chain fatty acid and / or the glycerin fatty acid ester containing the medium-chain fatty acid and the fat metabolism-related enzyme expression enhancer is determined according to the purpose, administration form, type of administration, age, sex, weight, and symptoms. Although it varies depending on conditions such as degree and health status, it is not specified, but it is contained to the extent that it exerts its functions on adipose tissue.
- the present invention relates to a lipid metabolism-related enzyme expression enhancer comprising a medium chain fatty acid and / or a glycerin fatty acid ester containing a medium chain fatty acid as an active ingredient.
- the expression enhancement of the enzyme related to lipid metabolism refers to a long-chain acyl CO dehydrase, an acyl CO A, which is one of a group of lipid oxidizing enzymes studied in completing the present invention. It shows an increase in mRNA expression level of oxidase, cal-tin palmitoyltransferase 2.
- body fat degraded by hormone-sensitive lipase was suitably consumed, particularly, once released into the blood. It is expected that free fatty acids will be taken up again by adipose tissue and will be suitably consumed, and will have the effect of reducing body fat as described below.
- the present invention provides a long-chain acyl-CoA dehydrogenase expression enhancer comprising a medium-chain fatty acid and Z or a glycerin fatty acid ester containing a medium-chain fatty acid as an active ingredient, an acyl-coA oxidase expression enhancer, carnitine Palmitoyltransferase 2 expression enhancer, preferably a long-chain acyl-COA dehydrogenase expression enhancer containing medium-chain fatty acid triglyceride as an active ingredient, an acyl-COA oxidase expression enhancer, cal- Chimpalmitoyltransferase 2 expression enhancer.
- the expression of long-chain acyl COA dehydrogenase, the expression of acyl COA oxidase, and the enhanced expression of carnitine palmitoyltransferase 2 can also be used as indicators of the lipid metabolism.
- long-chain acyl COA dehydrogenase, the expression of acyl COA oxidase, and the increase of mRNA expression of carnitine palmitoyltransferase 2 are observed, it is considered that the expression of the lipid metabolism-related enzyme is enhanced. Be considered.
- RNA expression levels of the enzyme by measuring in real time quantitative PC R using specific primers, we are sure quantitatively calculated increase or decrease.
- the method for quantifying mRNA expression was based on a standard curve prepared by converting total RNA derived from adipose tissue of the same age in rats fed normal chow into DNA with reverse transcriptase as a standard. , evaluated by a relative value of the mRNA Alpha expression level of the enzyme with respect to mRNA Alpha expression level of ⁇ Akuchin housekeeping gene was calculated by 0/0, it is compared to that of rats were fed a long chain fatty acid triglyceride are doing.
- any of these enzymes can be used in comparison with long-chain fatty acid triglyceride (LCT) intake.
- LCT long-chain fatty acid triglyceride
- the content of the medium-chain fatty acid and / or the glycerin fatty acid ester containing the medium-chain fatty acid in the whole trioxidation-related enzyme expression enhancer of the present invention is particularly limited as long as the content thereof has the trioxidation-related enzyme expression enhancing effect. Not done.
- the term "contained as an active ingredient” refers to an oxidation-related enzyme, specifically, a long-chain acyl-C dehydrogenase and / or an acyl-CoA oxidase and Z- or caltin-palmitoyltransferase 2 Is contained to such an extent that mRNA expression is enhanced, but the content is not particularly limited and may be appropriately adjusted depending on the frequency of intake, the amount of intake, and the purpose of use. The dose required to obtain the effect depends on the form of ingestion, the sex, weight, physical condition, etc.
- lg / day or more preferably 5 g / day or more, particularly preferably Can be exemplified as '10 g / day or more.
- the content is not particularly limited, but is, for example, 1% by mass or more, preferably 5% by mass or more, more preferably 5 to 99.9% by mass, and still more preferably 10 to 99.9% by mass. Particularly preferably, it is 13 to 99.9% by mass.
- the trioxidation-related enzyme expression enhancer contains a medium chain fatty acid and / or a glycerin fatty acid ester containing a medium chain fatty acid as a main component.
- a main component 50 to 99.9 mass. / 0 , preferably 70 to 99.9% by mass, more preferably 90 to 99.9% by mass.
- the same effect can be obtained by using MLCT or a structure with a smaller required amount as a medium-chain fatty acid.
- the content of the medium-chain fatty acid and / or the glycerin fatty acid ester containing the medium-chain fatty acid in the whole body of the present invention for improving the body fat or the subcutaneous fat is easily reduced.
- Enzyme expression enhancement There is no particular limitation as long as it has an effect.
- the term “containing as an active ingredient” means that the substance is contained to such an extent that the body fat is easily modified and the subcutaneous fat is easily modified, but the content is particularly limited. Rather, it may be adjusted as appropriate according to the frequency of intake, the amount of intake, and the purpose of use.
- the amount required to obtain the effect depends on the form of ingestion, the sex of the subject, weight, physical condition, etc., and is not particularly limited, but is, for example, 1 g Z days or more, preferably 5 g Z days or more, particularly Preferably, 10 g Z days or more can be exemplified.
- the content is not particularly limited, but is, for example, 1 mass% or more, preferably 5 mass% or more, and more preferably 5 to 99.9 mass. /. It is more preferably from 10 to 99.9% by mass, particularly preferably from 13 to 99.9% by mass.
- the content for obtaining the effect of the product of the present invention over a long period of time depends on the form of ingestion, the sex, weight, and physical condition of the subject, and is not particularly limited, but the above-mentioned content can be referred to. .
- the function is exhibited and the amount is not excessively taken, and the above content can be referred to.
- the modifying agent for the constitution that easily reduces the body fat and the constitution that easily reduces the subcutaneous fat can obtain the constitution modifying effect by a relatively long-term ingestion.
- the body constitution for example, when eating a diet that is free of medium-chain fatty acids and / or glycerin fatty acid esters containing medium-chain fatty acids, the effect of reducing body fat is obtained. be able to.
- the amount required as a medium-chain fatty acid for obtaining a modifier effect on the constitution in which the body fat is easily reduced and the constitution in which the subcutaneous fat is easily reduced is not particularly limited as described above. 4 g Z days or more, preferably lg ZB or more, more preferably 2 g Z days or more, further preferably 5 g Z days or more, particularly preferably 8 g / day or more, most particularly preferably 10 g Z days or more.
- Parenteral administration includes, for example, intravenous injection, arterial injection, intramuscular injection, subcutaneous injection, intradermal injection, intraperitoneal injection, intraspinal injection, epidural injection, transdermal administration, pulmonary administration, nasal administration, Enteral administration, buccal administration, transmucosal administration, etc. are mentioned.
- Examples of the dosage form include injections, suppositories (such as rectal suppositories, urethral suppositories, vaginal suppositories), and external liquids (such as injections, Agents, mouth washes, poultices, inhalants, sprays, aerosols, enemas, paints, wipes, disinfectants, nasal drops, ear drops, etc.), patches, transdermal absorption tapes, skin External preparations, ointments (pasta, liniment, lotion, etc.) are examples.
- suppositories such as rectal suppositories, urethral suppositories, vaginal suppositories
- external liquids such as injections, Agents, mouth washes, poultices, inhalants, sprays, aerosols, enemas, paints, wipes, disinfectants, nasal drops, ear drops, etc.
- patches transdermal absorption tapes
- Formulations for oral administration include, for example, tablets for internal use (uncoated tablets, sugar-coated tablets, coated tablets, enteric-coated tablets, chewable tablets, etc.) and oral tablets (pacal tablets, sublingual tablets, troche tablets, adhesive tablets, etc.) , Powders, capsules (hard capsules, soft capsules, etc.), granules (coated, pills, troches, liquids, or pharmaceutically acceptable sustained-release preparations thereof) And the like.
- Liquid preparations for oral administration include, for example, liquid preparations for internal use, shaking mixtures, suspensions, emulsions, syrups, dry syrups, elixirs, dips, decoctions, limonade, etc. Is not particularly limited.
- compositions are formulated together with pharmacologically acceptable bases, carriers, excipients, binders, disintegrants, lubricants, coloring agents, etc., according to known pharmaceutical manufacturing methods. Is administered.
- Carriers and excipients used in these preparations include, for example, sugars (lactose, saccharose, pudose sugar, etc.), starch (corn, potato, wheat), mannitol, calcium carbonate, calcium phosphate, calcium sulfate, and crystalline cellulose.
- sugars lactose, saccharose, pudose sugar, etc.
- starch corn, potato, wheat
- mannitol calcium carbonate
- calcium phosphate calcium sulfate
- crystalline cellulose examples include lulose, microcrystalline cellulose, canzo powder and gentian powder.
- binders used in these preparations fc include, for example, starch, tragacanth gum, gelatin, syrup, polyvinylinoleanolone, polyvinyleneoleate, polyvinylinolepyrrolidone, hydroxypropinoresenolellose, methylcellulose, ethyl Cellulose, canoleboximethi, lusenorelose and the like.
- Disintegrants used in these preparations include, for example, starch, agar, gelatin powder, sodium carboxymethylcellulose, calcium carboxymethylcellulose, crystalline cellulose, calcium carbonate, sodium hydrogencarbonate, sodium alginate and the like.
- Lubricants used in these preparations include, for example, magnesium stearate, tanolek, hydrogenated vegetable oil, macrogol and the like.
- coloring agents used in these preparations those permitted to be added to pharmaceuticals can be used.
- pH adjusters When preparing injections, if necessary, pH adjusters, buffers, stabilizers, solubilizers, etc. are added, and each injection is prepared in a conventional manner.
- white bran When preparing tablets and granules, as necessary, white bran, gelatin, hydroxypropylcellulose, purified shellac, gelatin, glycerin, sonorebitone, ethylsenorellose, hydroxypropinoresenorelose, It may be coated with hydroxypropyl methinolecellulose, polyvinylinolepyrrolidone, cenorellose acetate phthalate, hydroxypropinolemethinoresenolyl phthalate, methyl methacrylate, methacrylic acid polymer, etc. You may coat with the above layers. Further, capsules made of a substance such as ethyl cellulose or gelatin may be used.
- medium-chain fatty acid and Z or medium-chain fat contained in each functional agent of the present invention.
- glycerin fatty acid esters containing fatty acids are oily components, their solubility in nutrients and physiological functions, such as vitamins, vitamin 0, vitamin E, ascorbic acid fatty acid esters, lignan, coenzyme Q, and phosphorus Lipids, triterpenes, oryzanol, etc. can be added.
- examples of the form of the external preparation include solid, semi-solid, semi-solid, and liquid preparations for transdermal administration or transmucosal administration such as intraoral or nasal administration.
- liquid preparation examples include pharmaceutically acceptable emulsions or emulsions such as lotions, tinctures for external use, and liquid preparations for transmucosal administration.
- the formulation contains commonly used diluents, for example, ethanol, oils, emulsifiers and the like.
- semisolid preparations include ointments such as oily ointments and hydrophilic ointments.
- This preparation contains water, petrolatum, polyethylene glycol, oil, surfactant and the like as a commonly used base or carrier.
- semisolid or solid preparations include patches for transdermal or transmucosal (intraoral, nasal) administration such as plasters (rubber plaster, plaster, etc.), films, tapes, and cataplasms And the like.
- This preparation can be used as a commonly used base or carrier, for example, rubber-based polymers such as natural rubber, synthetic rubber such as putadiene rubber, SBR and SIS, mud-forming agents such as gelatin, kaolin and zinc oxide, and carboxymethyl cellulose.
- hydrophilic polymers such as sodium and sodium polyacrylate, tackifiers such as acrylic resin, liquid paraffin, water, other oils, and surfactants.
- the body fat reducing effect of the present invention can be measured by the amount of body fat in the total body weight of the animal. After long-term continuous ingestion of the product of the present invention or the long-chain fatty acid triglyceride to test animals, visceral fat such as perirenal adipose tissue, epididymal adipose tissue and mesenteric adipose tissue is combined with subcutaneous fat. It can be determined by comparing the amount of body fat in the body per body weight.
- the product of the present invention shows a significant reduction in visceral fat only, subcutaneous fat only, or body fat obtained by combining them, as compared to LCT intake.
- the weight of visceral fat alone, the weight of subcutaneous fat alone, and the weight of body fat obtained by combining them alone are 9.1%, 14.6%, and 12.0%, respectively, as compared with LCT intake. Since a significant decrease of% was recognized, a suitable body fat reducing agent can be obtained according to the present invention.
- Medium-chain fatty acid triglycerides and the like have the above-mentioned body fat decomposition promoting function and body fat blood release promoting function, and as a result, have an effect of reducing accumulated body fat.
- glycerin fatty acid triesters accumulated as body fat are decomposed into free fatty acids, which are reduced by transferring into the blood.
- the amount of mRNA expression of long-chain acyl CO dehydrogenase in hepatocytes and the amount of mRNA expression of CPT 2 or acyl CO oxidase in adipose tissue, particularly subcutaneous adipocytes were measured by LCT.
- Increased body fat degradation promoting activity is shown by the increase compared to when ingested, and the body fat (free fatty acid) that is broken down and released into the blood is suitable for hepatocytes and also fat cells And a more suitable body fat reduction effect can be obtained. Even when the free fatty acids from which the body fat has been decomposed and released are re-incorporated into the adipose tissue, the free fatty acids are suitably consumed, thereby exhibiting a suitable body fat reducing effect.
- the body fat reducing effect of the present invention differs from the conventionally known low body fat accumulating property in the content of the effect.
- Low body fat accumulation simply means medium-chain fatty acids It is an effect that fat is hard to accumulate because triglycerides and the like easily become energy, and the body fat reducing effect found in the present invention is based on ingestion and continuous ingestion. This indicates that body fat accumulated so far is reduced by decomposition and the like.
- the increase in mRNA expression of; 3 oxidation enzyme in hepatocytes indicates that lipid metabolism is promoted, and one of the proteins related to diet-induced thermogenesis is uncoupled.
- the increase in the mRNA expression level of protein ⁇ 2 also indicates that the heat production was promoted.
- the increased expression of mRNA such as hormone-sensitive lipase in adipocytes, particularly subcutaneous adipocytes, promoted body lipolysis, and that the body was degraded and released into the blood. Fat (free fatty acid) is considered to be suitably consumed in hepatocytes and adipocytes because the expression of lipid metabolism-related enzymes is enhanced.
- the body fat accumulated as body fat is decomposed, transferred to the blood, converted to energy in the liver, and partly consumed when it returns to fat cells. It can be said that it is a circulation, and the slimming agent effect is preferable. It is also preferable because it is a cycle of suitable utilization of human body energy.
- the present invention relates to enhancing expression of lipid metabolism-related enzymes containing medium-chain fatty acids and / or glycerol fatty acid esters containing medium-chain fatty acids as active ingredients, enhancing expression of peroxisome mitochondrion / 3-oxidizing enzymes, and acyl COA oxidation.
- the present invention relates to an oil and fat composition for enhancing the expression of oxidizing enzymes such as enzymes, carnitine palmitoyltransferase 2, and long-chain acyl-CoA dehydrogenase, and for modifying body fat, particularly subcutaneous fat, to a constitution that is easily reduced.
- Medium chain fatty acids and / or glycerin fatty acid esters containing medium chain fatty acids Can be obtained from fats and oils, and because of its good solubility in fats and oils, it is also a form of the lipid metabolism-related enzyme expression enhancer of the present invention.
- a preferred form of the food or drink for enhancing the expression of an enzyme is a fat or oil composition containing a medium-chain fatty acid and / or a glycerin fatty acid ester containing a medium-chain fatty acid. Further, when producing a glycerin fatty acid ester containing a medium-chain fatty acid, the oil and fat composition is produced, which is preferable.
- the content of the medium-chain fatty acid and the glycerin fatty acid ester containing the medium-chain fatty acid in the fat or oil composition is the content of the agent when used as an agent, and the content of the food or drink when used as a food or drink. It is.
- the content varies depending on the amount used in foods and drinks, but is, for example, 10 to 90% by mass / 0 , preferably 20 to 80% by mass or more, and more preferably. Can be 30 to 70% by mass or more.
- the form of the oil / fat composition may be any of liquid, solid, and semi-solid, and is not particularly limited.
- the oil / fat composition of the present invention comprises the above-mentioned lipid metabolism-related enzyme expression enhancer, peroxisome mitochondria / 3 oxidation enzyme expression enhancer, acyl COA oxidase, cal-tin palmitoyl transferase 2, and long chain acyl C.
- An enhancer of expression of j3 oxidative enzymes such as A dehydrogenase, a form of agent for improving body fat, especially for reducing body fat, especially subcutaneous fat.
- oxidases such as acyl CoA oxidase, carnitine palmitoyltransferase 2, and long-chain acyl CoA dehydrogenase
- oxidases such as acyl CoA oxidase, carnitine palmitoyltransferase 2, and long-chain acyl CoA dehydrogenase
- the oil / fat composition of the present invention can be obtained by subjecting an oil / fat containing a medium-chain fatty acid triglyceride as a raw material to a transesterification treatment as described above.
- the oil / fat composition of the present invention obtained as described above can be used as it is, or as a cooking oil / fat composition by mixing additives usually used in cooking oil / fat compositions.
- additives examples include polyglycerin fatty acid esters, sucrose fatty acid esters, and sorbitan fatty acid esters for the purpose of improving storage stability, improving oxidative stability, improving thermal stability, suppressing crystallization at low temperatures, and the like.
- polyglycerin fatty acid esters sucrose fatty acid esters, and sorbitan fatty acid esters for the purpose of improving storage stability, improving oxidative stability, improving thermal stability, suppressing crystallization at low temperatures, and the like.
- the above-mentioned hormone-sensitive lipase expression enhancer, 3-adrenaline receptor expression enhancer, body fat degradation promoter, body fat blood release promoter, lipid metabolism-related enzyme expression enhancer, body fat reducer, Additives and the like which can be added in the slimming agent can also be blended.
- the oil / fat composition of the present invention has a flavor equal to or higher than ordinary edible oils such as rapeseed oil, corn oil, safflower oil, and soybean oil, and is used for cooking stir-fry, fried food, marinade, etc. Not only can it be used, but it can also be used for foods containing fats and oils such as dressings, mayonnaise, margarine, confectioneries, cakes and beverages.
- the flavor characteristics vary depending on the type of food, but it is possible to make a refreshing dish that takes advantage of the taste of the ingredients. Also, the degree of oil splash during frying is It is equal to or less than ordinary edible oil.
- the present invention is directed to enhancing expression of lipid metabolism-related enzymes containing medium-chain fatty acids and Z or glycerin fatty acid esters containing medium-chain fatty acids, peroxisome mitochondrial j3 oxidizing enzyme expression, and acyl COA oxidation.
- Enzymes, carnitine palmitoyltransferase2, long-chain acetyl CO dehydrogenase, etc.] 3 Enhance expression of oxidative enzymes, and improve foods and drinks to improve body fat, especially subcutaneous fat.
- Foods and drinks containing medium-chain fatty acids and / or glycerin fatty acid esters containing medium-chain fatty acids, preferably medium-chain fatty acid triglycerides, are suitably orally ingested by eating and drinking to enhance the expression of lipid-metabolism-related enzymes.
- Increased expression of mitochondrial oxidizing enzymes increased expression of i3 oxidizing enzymes such as acyl-COA oxidase, virulentin palmitoyltransferase 2, long-chain acetyl-COA dehydrogenase, and reduced body fat, especially subcutaneous fat This is a preferred form because it has a modifying effect on the constitution.
- Medium-chain fatty acids and / or glycerin fatty acid esters containing medium-chain fatty acids enhance lipid metabolism-related enzyme expression, peroxisomal mitochondrial oxidase-related enzyme expression, acyl COA oxidase, carutin palmitoyltransferase 2, long chain acyl C o Oral ingestion is a preferred form for enhancing the expression of oxidizing enzymes such as A dehydrogenase, reducing body fat, and exhibiting a slimming effect.
- the form of food and drink is preferred.
- the intake is not particularly limited, the intake of the above-mentioned various agents can be referred to.
- the content of the food or drink can be adjusted depending on the number of times of intake, the amount, etc., and is not particularly limited.
- medium-chain fatty acids and / or glycerin fatty acid esters containing medium-chain fatty acids for example, 0.2 to 50% by mass, preferably 0.5 to 40% by mass, more preferably 1 to 20% by mass, Particularly preferably, it is 2 to 10% by mass, and in the case of a medium-chain fatty acid triglyceride, for example, 0.1 to 30% by mass, preferably 0.2 to 20% by mass. /. More preferably, 0.5 to 10% by mass, particularly preferably 1 to 5% by mass. /. Can be exemplified. ,
- acyl COA oxidase for enhancing the expression of peroxisome mitochondrial oxidizing enzymes, acyl COA oxidase, caltin palmitoyltransferase 2, long-chain acyl COA dehydrogenase, etc.
- acyl COA oxidase for enhancing the expression of peroxisome mitochondrial oxidizing enzymes, acyl COA oxidase, caltin palmitoyltransferase 2, long-chain acyl COA dehydrogenase, etc.
- 0-oxidation enzymes for improving body fat, especially subcutaneous fat, which is easily modified to reduce body fat
- the preferred content can be calculated from the content of the medium-chain fatty acid triglyceride.
- the form of the food and drink for enhancing the expression of lipid metabolism-related enzymes of the present invention is not particularly limited.
- the food and drink may be beverages, nutritional drinks, confectionery, karoe foods, oils and fats, dairy products, retort Examples include foods, range foods, frozen foods, seasonings, health supplements, etc.
- the shape and properties are not particularly limited, and may be any of solid, semi-solid, gel, liquid, powder, etc. Further, any of tablets, capsules, liquids, granules and the like may be used.
- lipid metabolism-related enzymes of the present invention such as enhanced expression of lipid metabolism-related enzymes of the present invention, peroxisome mitochondria] increased expression of oxidizing enzymes, acyl CoA oxidase, carnitine palmitoyl transferase 2, and long-chain acyl CO dehydrogenase
- oxidizing enzymes acyl CoA oxidase
- carnitine palmitoyl transferase 2 long-chain acyl CO dehydrogenase
- foods and drinks for enhancing the expression of oxidative enzymes, improving body fat, particularly reducing subcutaneous fat, and reducing body fat are listed below, but the present invention is limited to these. Not something.
- Increased expression of lipid metabolism-related enzymes of the present invention peroxisome mitochondria] Increased expression of oxidizing enzymes, acyl CoA oxidase, cal-tin palmitoyl transferase 2, long-chain acyl CO dehydrogenase, etc. (3) Increased expression of oxidative enzymes, body that can easily reduce body fat, especially subcutaneous fat There are no particular restrictions on the form, etc.
- Japanese confectionery such as oysters, rice crackers, rice crackers, buns, buns, candies, woodpeckers, biscuits, crackers, Pies, castellas, donuts, pudding, sponge cakes, waffles, putter cream, custard cream, cream puffs, chocolate, chocolate confectionery, karamenore, candees, chewing gum, jelly, hot cakes, bread, confectionery bread, and other sweets and potatoes Chips and other snacks, ice cream, ice candy, sherbet and other frozen desserts, lactic acid drinks, lactic acid drinks, concentrated milky drinks, juice drinks, pulp drinks, functional drinks, soft drinks such as carbonated drinks, green tea, black tea,
- Coffee and cocoa Beverages fermented milk, processed milk, dairy products such as cheese, processed soybean foods such as soy milk, tofu, jam, fruit syrup pickles, flower paste, peanut paste, phenolic paste, pickles, etc.
- Cereal products such as udon noodles, pasta, etc., meat products such as ham, sausage, bacon, dry sausage, beef jerky, and pomberg, fish ham, fish sausage, kamaboko, chikuwa, and fish and shellfish products such as starch , Dried fish such as fish and shellfish, various sections such as bonito, mackerel, aji, etc., ⁇ -, salted fish such as squid, squid, fish and other dried fish, smoked products such as salmon, glue, small fish, shellfish, wild vegetables, shiitake mushrooms Food, miso, soy sauce, sauce, ketchup, puoyon, grilled meat sauce, kare ichiru, stew sauce, soup sauce Various seasonings such as soup stock, cooked rice, oils and fats and processed products such as margarine, shortening, mayonnaise and dressing, and various ranges and frozen foods containing oils and fats.
- rice and various seasonings, and oils and fats and processed products such as margarine, shortening, mayonnaise, and dressing are preferred.
- the shape and properties are not particularly limited, and may be any of solid, semi-solid, gel, liquid, powder, and the like. Tablets, soft capsules, and hard capsules used as fillers, etc. Any processed capsules, liquids, granules, etc. may be used.
- Particularly preferred forms are foods and drinks in the form of fats and oils compositions, and foods and drinks cooked using the fats and oils composition, and foods and drinks mixed therewith.
- the medium-chain fatty acid triglyceride and the like are fats and oils and can be obtained in the process of producing the medium-chain fatty acid triglyceride, and thus are excellent in usability, stability, manufacturability, and the like.
- the uncoupling protein expression enhancer and the oil / fat composition can be blended. Moreover, it can also be obtained by cooking using the fat or oil composition.
- the lipid metabolism-related enzyme expression enhancer is preferred because it is expected to have a preventive and / or ameliorating effect on lifestyle-related diseases such as diabetes, arteriosclerosis, hyperlipidemia, and hypertension through these effects.
- medium-chain fatty acids and / or glycerin fatty acid esters containing medium-chain fatty acids are used as lipid metabolism-related enzyme expression enhancers, peroxisome / 3 and mitochondria / 3 oxidation enzyme expression enhancers, acyl C o A oxidase, cal-tin palmitoyltransferase 2, long-chain acyl C o A dehydrogenase, etc., an enhancer of the expression of oxidizing enzymes, for the purpose of improving body fat, especially for reducing subcutaneous fat It can be used as an agent.
- a medium chain fatty acid and a glycerin fatty acid ester containing Z or a medium chain fatty acid can be used as a slimming agent. Further, it can be used as an obesity preventive and / or therapeutic agent.
- the present invention relates to a lipid metabolism-related enzyme expression enhancer comprising a medium-chain fatty acid and / or a glycerin fatty acid ester containing a medium-chain fatty acid, a peroxisome j3 ⁇ mitochondria J3 oxidase-related enzyme expression enhancer, and acyl Co.
- Oxidative enzyme expression enhancers such as A oxidase, cal-tin palmitoyltransferase 2, long chain acyl CO dehydrogenase, body fat, especially subcutaneous fat It relates to the raw material of the modifying agent for the constitution that is easily reduced.
- the lipid metabolism-related enzyme expression enhancer of the present invention is characterized by containing a medium-chain fatty acid and / or a glycerin fatty acid ester containing a medium-chain fatty acid, whereby the lipid metabolism-related enzyme expression is enhanced, and peroxisome ⁇ mitochondria / 3 Increased expression of oxidizing enzymes, increased expression of / 3 oxidizing enzymes such as acyl-CoA oxidase, carnitine palmitoyltransferase 2, and long-chain acetyl-CoA dehydrogenase, and reduced body fat, especially subcutaneous fat It has a modifying effect on the constitution.
- medium-chain fatty acids and / or glycerin fatty acid esters containing medium-chain fatty acids, especially those containing medium-chain fatty acid triglycerides are used to express lipid metabolism-related enzymes, peroxisomes mitochondria / 3-oxidation enzymes Enhancer, acyl CoA oxidase, carnitine palmitoyltransferase 2, oxidizing enzyme expression enhancer such as long-chain acyl CoA dehydrogenase, modification to body fat, especially for reducing subcutaneous fat It is suitable as a raw material for an agent, and those containing a high concentration are particularly suitable as a raw material. Although the content is not particularly limited, for example, 50 to 99.9% by mass, preferably 70 to 99.9% by mass, and more preferably 90 to 99.9% by mass can be exemplified. .
- the mode of body lipolysis in the visceral and subcutaneous adipose tissues when a medium-chain fatty acid triglyceride was administered was compared with that when no medium-chain fatty acid triglyceride was administered.
- the control was performed by comparing changes over time in the expression levels of visceral and subcutaneous fat hormone-sensitive lipase and j33-adrenoceptor.
- 6-week-old male male Wistar rats were preliminarily reared for 1 week, then added to soybean oil, added to 100% medium-chain fatty acid triglyceride, and added to the oil / fat composition.
- the AIN93 standard diet was replaced with corn starch and all foods and water were given ad libitum. Body weight and food consumption were measured over time, and the animals were reared for 6 weeks. After that, the rats used in the test were fasted for 6 hours, and then the rats in each group were sacrificed and used for measuring the expression levels of hormonal-sensitive lipase in visceral subcutaneous fat and J33-adrenoceptor mRNA. did.
- hormone-sensitive lipase and ⁇ 3_adrenoceptor mRNA were measured as follows. That is, total RNA in the isolated epididymal fat and subcutaneous fat was homogenized with Isogen (manufactured by Futtsubon Gene), and then extracted with black form and isopropyl alcohol to obtain total RNA.
- LCT soybean oil-added group
- MCT oil-fat composition containing 100% medium-chain fatty acid triglyceride
- the expression of UCP-2 mRNA at each site of the rat was measured in the same manner and in the same manner as in Example 1. However, in this example, the fasting time before the measurement was divided into 6 hours and 18 hours. The measurement sites were the liver, epididymal fat, and subcutaneous fat. The UCP-2 expression level was determined in the same manner as in Example 1. Table 3 shows the results.
- mice were forcibly orally administered 7,50 Omg / kg of emulsified fat / oil using a sonde.
- LCAD long-chain acetyl CoA dehydrogenase
- MCAD medium-chain acetyl CoA dehydrogenase
- SCAD short-chain acetyl CoA dehydrogenase
- the long, medium, and short chain acyl CoA dehydrogenase activities were measured as follows.
- the enzyme activity measurement fraction was prepared by adding a homogenate buffer (sucrose, EDTA containing Tris-HCl buffer, pH 7.2) to the excised liver at 7 times its weight, and stirring with a homogenizer.
- the obtained homogenate solution was centrifuged several times, and the supernatant fraction obtained was used for enzyme activity measurement.
- the oxygen activity was measured by a colorimetric method. That is, 2,6-dichloromouth indophenol (manufactured by Sigma), N-methylmaleimide (manufactured by Sigma) and 100 mM phosphate buffer pH 7.5 were added to the separated enzyme solution.
- the results showed that the enzyme activity of LCAD was higher in the group receiving 25% MCT and the group receiving MCT than in the group receiving LCT.
- the above measurement was performed for a time sufficient to affect the liver ingestion, and it was expected that the LCAD enzyme activity would be higher than in the MCT ingestion group, etc.
- the enzyme activity of the group receiving 25% of MCT was higher. It was found that the MCT group that did not contain long-chain fatty acids had the effect of enhancing LCAD enzyme activity, which is an interesting result.
- the mRNA expression level of UCP-2 is much higher in rats with MIX25. That is, it can be seen that the mRNA expression level of UCP-2 in the liver immediately after ingestion was highest in rats with MIX 25, and then in the MCT group. The value of the mRNA expression level of UCP-2 was determined in the same manner as in Example 1.
- 6-week-old male Wistar rats After breeding 6-week-old male Wistar rats, they were divided into two groups (20 each) consisting of a soybean oil-supplemented group and an oil-fat composition containing 100% medium-chain fatty acid triglyceride. All sucrose was replaced with corn starch, and an experimental food and water were provided ad libitum. After a 6-week rearing, the rats in each group were sacrificed, and the liver and visceral fat (peritesticular fat, mesenteric fat, perirenal fat) were removed and the weight was measured. Measurement did.
- the internal organs of the carcass were excised, freeze-dried, and the subcutaneous fat was calculated from the total fat mass obtained by the Soxhlet method and the carcass weight, and the body fat mass was calculated in conjunction with the visceral fat mass. The weight was calculated.
- tablet compositions were prepared according to the formulation shown in Table 7 and the following production method.
- each substance was mixed well, and this mixture was tableted to obtain a tablet composition of 300 mg per tablet.
- a capsule composition was prepared according to the formulation shown in Table 8 and the following production method.
- a medium-chain fatty acid triglyceride and lactose are mixed well, and then hydroxypropyl cellulose is added to granulate. This was dried, granulated, and mixed with soft soft anhydride to obtain a powder.
- Components 1) and 3) to 5) are mixed and dissolved.
- Table 1 1 shows the formulation and c tool Table 1 1 were prepared emulsions by the following method>
- Components 9) to 13) are mixed by heating and kept at 70 ° C.
- the mixture at the above mixing ratio was added with water, molded, and heated and dried in an oven to obtain a spherical cereal food.
- an edible oil mixture was prepared according to the formulation shown in Table 15 and the following production method.
- margarine was prepared by the formulation shown in Table 16 and the following production method. Table 16>
- the above raw materials were mixed by a conventional method, and quenched and kneaded using a combinator to obtain margarine.
- the mixture was stirred for 25 minutes while maintaining the temperature at 90 ° C. Then cool to 20 ° C and mix with soy salad oil and medium chain fatty acid triglyceride.
- the raw materials excluding soybean salad oil, medium-chain fatty acid triglyceride, and salted egg yolk were heated to 90 ° C with mixing and stirring, and stirred for 25 minutes while maintaining the temperature at 90 ° C. After cooling to 20 ° C, soybean salada oil, medium-chain fatty acid triglyceride, and salted egg yolk were combined and stirred under reduced pressure to obtain mayonnaise.
- margarine was prepared according to the formulation shown in Table 19 and the following production method.
- O g Storage 4 A 0, 0 U g ⁇ Water 17.
- dressings were prepared according to the formulation shown in Table 20 and the following production method.
- the raw materials except for the oil and fat composition A and the salted egg yolk were heated to 90 ° C while mixing and stirring, and stirred for 25 minutes while maintaining the temperature at 90 ° C. After cooling to 20 ° C, the oil composition A and the salted egg yolk were combined and stirred under reduced pressure to obtain mayonnaise.
- the lipid metabolism-related enzyme expression enhancer of the present invention peroxisome / 3 Mitochondria] 3 Oxidative enzyme expression enhancer, oxidative enzyme expression enhancer such as acyl CoA oxidase, carnitine palmitoyltransferase 2, long chain acyl CoA dehydrogenase, body fat, especially subcutaneous fat
- a modifying agent or the like for the constitution that can easily reduce slimming, an excellent slimming effect and treatment of various diseases can be achieved.
- medium-chain fatty acids and / or glycerin fatty acid esters containing medium-chain fatty acids are safe for the human body, and the effects of the present invention can be obtained by ingesting them naturally in meals and the like.
- the constitutional modifier is used, for example, to make the body more easily lean, so that the effect can be obtained even when the functional agent of the present invention is not taken.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003261928A AU2003261928A1 (en) | 2002-09-05 | 2003-09-04 | Agents, foods and drinks controlling lipid metabolism |
JP2004534154A JPWO2004022050A1 (ja) | 2002-09-05 | 2003-09-04 | 脂質代謝調整剤および飲食物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-260673 | 2002-09-05 | ||
JP2002260673 | 2002-09-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004022050A1 true WO2004022050A1 (ja) | 2004-03-18 |
Family
ID=31973105
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/011293 WO2004022050A1 (ja) | 2002-09-05 | 2003-09-04 | 脂質代謝調整剤および飲食物 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JPWO2004022050A1 (ja) |
AU (1) | AU2003261928A1 (ja) |
WO (1) | WO2004022050A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009151094A1 (ja) * | 2008-06-11 | 2009-12-17 | 株式会社リコム | ヒトアドレナリンβ3受容体リガンド、これを含む食品及び医薬品 |
WO2012105130A1 (ja) * | 2011-01-31 | 2012-08-09 | 日清オイリオグループ株式会社 | インスリン分泌促進用油脂組成物 |
JP2015012843A (ja) * | 2013-07-08 | 2015-01-22 | 株式会社アマケンテック | ナノオーダー分散処理飲料、ナノオーダー分散処理調味料、ナノオーダー分散処理飲料の製造方法及びナノオーダー分散処理調味料の製造方法 |
JP5702292B2 (ja) * | 2009-09-30 | 2015-04-15 | 日清オイリオグループ株式会社 | パーキンソン病患者の内臓脂肪減少抑制剤 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1985003863A1 (en) * | 1984-03-01 | 1985-09-12 | Baxter Travenol Laboratories, Inc. | Method for directed visceral metabolism of medium chain triglyce rides |
WO2000045649A1 (en) * | 1999-02-05 | 2000-08-10 | Baylor University Medical Center | Nutritional supplement or pharmaceutical preparation comprising triglycerides with seven-carbon fatty acid |
WO2000074497A1 (en) * | 1999-06-07 | 2000-12-14 | Aveve N.V. | The combined use of triglycerides containing medium chain fatty acids and exogenous lipolytic enzymes as feed supplements |
WO2002011552A2 (en) * | 2000-08-08 | 2002-02-14 | Kao Corporation | Oil/fat composition |
JP2002322052A (ja) * | 2001-04-26 | 2002-11-08 | Kao Corp | 小腸上皮中の脂質代謝改善剤 |
-
2003
- 2003-09-04 WO PCT/JP2003/011293 patent/WO2004022050A1/ja active Application Filing
- 2003-09-04 AU AU2003261928A patent/AU2003261928A1/en not_active Abandoned
- 2003-09-04 JP JP2004534154A patent/JPWO2004022050A1/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1985003863A1 (en) * | 1984-03-01 | 1985-09-12 | Baxter Travenol Laboratories, Inc. | Method for directed visceral metabolism of medium chain triglyce rides |
WO2000045649A1 (en) * | 1999-02-05 | 2000-08-10 | Baylor University Medical Center | Nutritional supplement or pharmaceutical preparation comprising triglycerides with seven-carbon fatty acid |
WO2000074497A1 (en) * | 1999-06-07 | 2000-12-14 | Aveve N.V. | The combined use of triglycerides containing medium chain fatty acids and exogenous lipolytic enzymes as feed supplements |
WO2002011552A2 (en) * | 2000-08-08 | 2002-02-14 | Kao Corporation | Oil/fat composition |
JP2002322052A (ja) * | 2001-04-26 | 2002-11-08 | Kao Corp | 小腸上皮中の脂質代謝改善剤 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009151094A1 (ja) * | 2008-06-11 | 2009-12-17 | 株式会社リコム | ヒトアドレナリンβ3受容体リガンド、これを含む食品及び医薬品 |
JP5702292B2 (ja) * | 2009-09-30 | 2015-04-15 | 日清オイリオグループ株式会社 | パーキンソン病患者の内臓脂肪減少抑制剤 |
WO2012105130A1 (ja) * | 2011-01-31 | 2012-08-09 | 日清オイリオグループ株式会社 | インスリン分泌促進用油脂組成物 |
JP2012158544A (ja) * | 2011-01-31 | 2012-08-23 | Nisshin Oillio Group Ltd | インスリン分泌促進用油脂組成物 |
JP2015012843A (ja) * | 2013-07-08 | 2015-01-22 | 株式会社アマケンテック | ナノオーダー分散処理飲料、ナノオーダー分散処理調味料、ナノオーダー分散処理飲料の製造方法及びナノオーダー分散処理調味料の製造方法 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2004022050A1 (ja) | 2005-12-22 |
AU2003261928A1 (en) | 2004-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101268206B1 (ko) | 당뇨병용 식품 | |
CA2417971C (en) | Oil/fat composition | |
CA2418348C (en) | Oil/fat composition | |
JP4870430B2 (ja) | 下肢静脈瘤予防・治療用組成物 | |
US20070141220A1 (en) | Composition enriched in diglyceride with conjugated linoleic acid | |
US20040151824A1 (en) | Oil composition | |
JPWO2003074043A1 (ja) | 体温上昇剤 | |
JP2001262180A (ja) | 油脂組成物 | |
WO2004022049A1 (ja) | 痩身剤およびその飲食物 | |
WO2004000299A1 (ja) | 体脂肪分解促進剤および飲食物 | |
JP2002302441A (ja) | 月経前症候群症状緩和用組成物及び飲食物 | |
WO2004022050A1 (ja) | 脂質代謝調整剤および飲食物 | |
WO2004022051A1 (ja) | ペルオキシソーム増殖薬活性化受容体調整剤 | |
JP5066856B2 (ja) | アディポネクチン分泌促進剤 | |
KR100684641B1 (ko) | 유지 조성물, 이를 함유하는 식품 및 건강보조식품 | |
JP5479696B2 (ja) | 生体内のプラスマローゲン増加剤 | |
JPWO2003074042A1 (ja) | 脱共役蛋白質発現亢進剤 | |
JP2007045789A (ja) | 食後高インスリン血症改善剤 | |
JP2003055216A (ja) | 月経中症状緩和剤及びそれを含有する飲食物 | |
JP2023055836A (ja) | 血管内皮機能の改善用組成物 | |
JP2002029967A (ja) | 月経前症候群症状緩和用食用油脂組成物 | |
EP3750533A1 (en) | Agent for improving lymphatic circulation | |
WO2004080209A1 (ja) | 血清レムナント様リポタンパク濃度調整剤 | |
JPWO2003092396A1 (ja) | 体脂肪低下用油脂組成物、及びそれを含有する食品 | |
WO2008153220A1 (ja) | 血管疾患の予防又は治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004534154 Country of ref document: JP |
|
122 | Ep: pct application non-entry in european phase |